The Piedmont Triad Regenerative Medicine Engine (PTRME), funded by the National Science Foundation (NSF), has awarded six regional companies $2.5 million in grants as part of its inaugural Ecosystem ...

Referring to cancer as a “battle” minimizes the many real issues faced by cancer patients who must live with nausea, pain, ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

Shares of NeoGenomics tumbled after the oncology testing-services company said its chief executive, Chris Smith, will retire April 1. The stock fell 20%, to $14.91, in afternoon trading Friday. Shares ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...